Adamis Pharmaceuticals Corporation - Product Pipeline Review - 2012

Global Markets Direct, August 2012, Pages: 44

Adamis Pharmaceuticals Corporation – Product Pipeline Review – 2012

Summary

Global Markets Direct’s pharmaceuticals report, “Adamis Pharmaceuticals Corporation - Product Pipeline Review - 2012” provides data on the Adamis Pharmaceuticals Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Adamis Pharmaceuticals Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Adamis Pharmaceuticals Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Adamis Pharmaceuticals Corporation - Brief Adamis Pharmaceuticals Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Adamis Pharmaceuticals Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Adamis Pharmaceuticals Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Adamis Pharmaceuticals Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Adamis Pharmaceuticals Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Adamis Pharmaceuticals Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Adamis Pharmaceuticals Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Adamis Pharmaceuticals Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Adamis Pharmaceuticals Corporation and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Adamis Pharmaceuticals Corporation; Adamis Pharmaceuticals Corporation - Key Therapeutics; Adamis Pharmaceuticals Corporation - Pipeline Overview and Promising Molecules; Adamis Pharmaceuticals Corporation - News; Adamis Pharmaceuticals Corporation - Latest Updates; Adamis Pharmaceuticals Corporation - Pipeline; Adamis Pharmaceuticals Corporation - Discontinued/Dormant Projects

2
List of Tables 4
List of Figures 4
Adamis Pharmaceuticals Corporation Snapshot 5
Adamis Pharmaceuticals Corporation Overview 5
Key Information 5
Key Facts 5
Adamis Pharmaceuticals Corporation – Research and Development Overview 6
Key Therapeutic Areas 6
Adamis Pharmaceuticals Corporation – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Adamis Pharmaceuticals Corporation – Pipeline Products Glance 10
Adamis Pharmaceuticals Corporation – Late Stage Pipeline 10
Registration Filed Products/Combination Treatment Modalities 10
Adamis Pharmaceuticals Corporation Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Adamis Pharmaceuticals Corporation – Early Stage Pipeline Products 13
Pre-Clinical Products/Combination Treatment Modalities 13
Adamis Pharmaceuticals Corporation – Drug Profiles 14
APC-100 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
APC-1000 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
APC-200 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
APC-300 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
APC-3000 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Savvy 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
TeloB-VAX 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Adamis Pharmaceuticals Corporation – Pipeline Products by Route of Administration 24
Adamis Pharmaceuticals Corporation – Pipeline Products By Mechanism of Action 25
Adamis Pharmaceuticals Corporation – Recent Pipeline Updates 26
Adamis Pharmaceuticals Corporation - Discontinued Pipeline Products 29
Discontinued Pipeline Product Profiles 29
Savvy 29
Adamis Pharmaceuticals Corporation – Locations And Subsidiaries 30
Head Office 30
Financial Deals Landscape 31
Adamis Pharmaceuticals Corporation, Deals Summary 31
Adamis Pharmaceuticals Corporation, Pharmaceuticals & Healthcare, Deal Details 32
Asset Transactions 32
Adamis Pharma Acquires Cancer Vaccine Technology From The Regents Of The University Of California 32
Partnerships 33
Adamis Enters Into Co-Development Agreement With Beximco 33
Licensing Agreements 34
Adamis Pharma Enters Into Licensing Agreement With Colby Pharma 34
Equity Offering 36
Adamis Pharma Completes Final Tranche Of Private Placement Of Shares For $0.5 Million 36
Debt Offering 38
Adamis Pharma Completes Private Placement Of Senior Convertible Note For $0.5 Million 38
Adamis Pharma Completes Private Placement Of Senior Convertible Note Due 2013 For $1 Million 39
Adamis Pharma Completes Private Placement Of Senior Secured Convertible Notes For $1.5 Million 40
Acquisition 41
Adamis Pharma Completes Acquisition Of Cellegy Pharma 41
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables
Adamis Pharmaceuticals Corporation, Key Information 5
Adamis Pharmaceuticals Corporation, Key Facts 5
Adamis Pharmaceuticals Corporation – Pipeline by Indication, 2012 7
Adamis Pharmaceuticals Corporation – Pipeline by Stage of Development, 2012 8
Adamis Pharmaceuticals Corporation – Monotherapy Products in Pipeline, 2012 9
Adamis Pharmaceuticals Corporation – Filed, 2012 10
Adamis Pharmaceuticals Corporation – Phase II, 2012 11
Adamis Pharmaceuticals Corporation – Phase I, 2012 12
Adamis Pharmaceuticals Corporation – Pre-Clinical, 2012 13
Adamis Pharmaceuticals Corporation – Pipeline By Route of Administration, 2012 24
Adamis Pharmaceuticals Corporation – Pipeline Products By Mechanism of Action, 2012 25
Adamis Pharmaceuticals Corporation – Recent Pipeline Updates, 2012 26
Adamis Pharmaceuticals Corporation - Discontinued Pipeline Products, 2012 29
Adamis Pharmaceuticals Corporation, Deals Summary 31
Adamis Pharma Acquires Cancer Vaccine Technology From The Regents Of The University Of California 32
Adamis Enters Into Co-Development Agreement With Beximco 33
Adamis Pharma Enters Into Licensing Agreement With Colby Pharma 34
Adamis Pharma Completes Final Tranche Of Private Placement Of Shares For $0.5 Million 36
Adamis Pharma Completes Private Placement Of Senior Convertible Note For $0.5 Million 38
Adamis Pharma Completes Private Placement Of Senior Convertible Note Due 2013 For $1 Million 39
Adamis Pharma Completes Private Placement Of Senior Secured Convertible Notes For $1.5 Million 40
Adamis Pharma Completes Acquisition Of Cellegy Pharma 41

List of Figures
Adamis Pharmaceuticals Corporation – Pipeline by Indication, 2012 7
Adamis Pharmaceuticals Corporation – Pipeline by Stage of Development, 2012 8
Adamis Pharmaceuticals Corporation – Monotherapy Products in Pipeline, 2012 9
Adamis Pharmaceuticals Corporation – Pipeline By Route of Administration, 2012 24
Adamis Pharmaceuticals Corporation - Pipeline Products By Mechanism of Action, 2012 25

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Scientific Games Corporation - Company Analysis
• Altera Corporation
• Bose Corporation
• SYNNEX Corporation
• Avocent Corporation - SWOT Analysis
• Ixia - Company Analysis
• Black & Decker Corporation - SWOT Analysis
• SanDisk Corporation
• Nortel Networks Corporation